Get ready for a vaccine data debate
The discussion over just which in-development Covid-19 vaccine is most promising will quickly move from theoretical to numerical, as we’re about to get the third major data release of the month.
On Monday, the Lancet will publish results from a Phase 1 study of a vaccine developed by Oxford University and AstraZeneca, the journal told Reuters. That follows early-stage data from Pfizer and BioNTech, uploaded to a preprint server earlier this month, and Phase 1 results from Moderna, published in the New England Journal of Medicine this week.
It also invites armchair immunologists the world over to make scientifically dubious cross-trial comparisons. The key metric for each study is the volume of neutralizing antibodies after vaccination. To the extent there’s a consensus, the Moderna and Pfizer/BioNTech vaccines appear roughly comparable, which means Oxford and AstraZeneca could shift the narrative by outperforming or falling short of the competition.
On Monday, the Lancet will publish results from a Phase 1 study of a vaccine developed by Oxford University and AstraZeneca, the journal told Reuters. That follows early-stage data from Pfizer and BioNTech, uploaded to a preprint server earlier this month, and Phase 1 results from Moderna, published in the New England Journal of Medicine this week.
It also invites armchair immunologists the world over to make scientifically dubious cross-trial comparisons. The key metric for each study is the volume of neutralizing antibodies after vaccination. To the extent there’s a consensus, the Moderna and Pfizer/BioNTech vaccines appear roughly comparable, which means Oxford and AstraZeneca could shift the narrative by outperforming or falling short of the competition.
No hay comentarios:
Publicar un comentario